Structure Therapeutics, Inc. (GPCR)
19.08
-1.28
(-6.29%)
USD |
NASDAQ |
Nov 05, 16:00
19.59
+0.51
(+2.67%)
After-Hours: 04:23
Structure Therapeutics SG&A Expense (TTM) : 74.01M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 74.01M |
| March 31, 2026 | 71.20M |
| December 31, 2025 | 61.72M |
| September 30, 2025 | 57.60M |
| June 30, 2025 | 56.13M |
| March 31, 2025 | 51.59M |
| December 31, 2024 | 49.44M |
| September 30, 2024 | 46.94M |
| June 30, 2024 | 42.23M |
| Date | Value |
|---|---|
| March 31, 2024 | 37.48M |
| December 31, 2023 | 32.66M |
| September 30, 2023 | 26.23M |
| June 30, 2023 | 21.36M |
| March 31, 2023 | 19.32M |
| December 31, 2022 | 16.19M |
| June 30, 2022 | 11.60M |
| March 31, 2022 | 7.840M |
| December 31, 2021 | 3.373M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Eli Lilly & Co. | 12.62B |
| Novo Nordisk A/S | 7.324B |
| Pfizer Inc. | 10.53B |
| Viking Therapeutics, Inc. | 62.40M |
| Liquidia Corp. | 192.66M |